# To Evaluate the Safety and Primary Immunogenicity of Cell-free (Three-component) Combination Vaccine for Phase I Immunogenicity in Children and Infants

> **NCT05189548** · PHASE1,PHASE2 · UNKNOWN · sponsor: **Changchun BCHT Biotechnology Co.** · enrollment: 72 (estimated)

## Conditions studied

- Safety、Immunogenicity

## Interventions

- **BIOLOGICAL:** A single-center and single-arm design was used to evaluate the safety and preliminary immunogenicity of the adsorbed cell-free leukiche (three-component) combination vaccine

## Key facts

- **NCT ID:** NCT05189548
- **Lead sponsor:** Changchun BCHT Biotechnology Co.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2021-12-10
- **Primary completion:** 2022-04-30
- **Final completion:** 2022-09-30
- **Target enrollment:** 72 (ESTIMATED)
- **Last updated:** 2022-01-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05189548

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05189548, "To Evaluate the Safety and Primary Immunogenicity of Cell-free (Three-component) Combination Vaccine for Phase I Immunogenicity in Children and Infants". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05189548. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*